# DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

> **NCT06820255** · PHASE4 · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 135 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
- Upper Tract Urothelial Cancer

## Interventions

- **DRUG:** Platinum + Gemcitabine
- **DRUG:** Avelumab first-line maintenance
- **DIAGNOSTIC_TEST:** NGS test for DDR alterations

## Key facts

- **NCT ID:** NCT06820255
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-01-07
- **Final completion:** 2027-01-07
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820255, "DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06820255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*